It is a genuine dilemma in this age of new-fangled “molecular” drugs, that some seem to work very well during their first human trials, but we have to wait years to get them to the public.
Of course there is massive cost to consider in some cases, but I don’t know about eteplirsen. Public health advocates can have a terrible time deciding if a few people can have an expensive drug vs. a lot of people getting a cheap one. For instance, how many doses of polio vaccine would you trade for one of eteplirsen? These are the realities of government budgets. I wouldn’t like to do it, would you?
Austin and Max Leclaire are brothers. Austin is older, Max is younger. Like most siblings, they have many things in common and just as many that set them apart. For now, though, their strongest bond is over something they share — Duchenne muscular dystrophy (DMD), the most common lethal genetic disorder among children. Duchenne’s hallmark is increasing muscle weakness that eventually makes it hard to breathe and confines kids to wheelchairs, which is where Austin finds himself these days. Now 14, he lost the ability to walk four years ago, a development that helps explain why the disease looks so different in the two brothers today.
Because Max, 11, was still able to put one foot in front of another in the summer of 2011, he was eligible to enroll in a drug trial for Eteplirsen, which is designed for children like the Leclaire brothers who have trouble producing a protein…
View original post 1,502 more words